Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemosol falls while Northfield rises in blood substitute arena

This article was originally published in Clinica

Executive Summary

Last week saw contrasting fortunes for two blood substitute makers vying for a share of the as-yet-untapped US market. In what was a crushing blow for Hemosol, the firm saw its stock plunge after cancelling a key trial of its flagship product, Hemolink. Northfield Laboratories, on the other hand, watched its shares rise following an announcement that it had come to a special agreement with the US FDA for its product, PolyHeme.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel